AUTOLUS THERAPEUTICS PLC

AUTL NASDAQ
15.86
+0.45
+2.92%
Closed 16:00 06/17 EDT
Open
15.65
Prev Close
15.41
High
16.02
Low
15.09
Volume
317.43K
Avg Vol (3M)
119.86K
52 Week High
53.24
52 Week Low
15.07
% Turnover
0.84%
Market Cap
599.11M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers AUTOLUS THERAPEUTICS PLC AUTL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.
MORE >

Recently

Name
Price
%Change